

### Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (previously presented) A pharmaceutical composition comprising 3 wt.% to 50 wt.% telmisartan dispersed in a dissolving matrix comprising:

- (a) a basic agent in a molar ratio of basic agent:telmisartan of 1:1 to 10:1;
- (b) about 1 wt.% to about 20 wt.% of polyoxamers having an average molecular weight of about 2000 to 12000;
- (c) 25 wt.% to 70 wt.% of a water-soluble diluent; and
- (d) 0 wt.% to 20 wt.% of one or more additional excipients and/or adjuvants,

wherein the sum of all components is 100%.

2. (original) The pharmaceutical composition of claim 1, wherein the basic agent is a metal hydroxide or a basic amino acid.

3. (original) The pharmaceutical composition of claim 1, wherein the basic agent is NaOH, KOH, NaHCO<sub>3</sub>, KHCO<sub>3</sub>, Na<sub>2</sub>CO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, Na<sub>2</sub>HPO<sub>4</sub>, K<sub>2</sub>HPO<sub>4</sub>, arginine, or meglumine.

4. and 5. (cancelled)

6. (currently amended) The pharmaceutical composition of claim 1, wherein the poloxamers are ~~is~~ poloxamer 182LF, poloxamer 331, or poloxamer 188.

7. (original) The pharmaceutical composition of claim 1, wherein the water-soluble diluent is selected from carbohydrates, oligosaccharides, and sugar alcohols.

8. (currently amended) The pharmaceutical composition of claim 1, wherein the water-soluble diluent is ~~selected~~ glucose, sucrose, erythritol, sorbitol, mannitol, dulcitol, ribitol, ~~and~~ or xylitol.

9. (original) The pharmaceutical composition of claim 1, wherein the additional excipients and/or adjuvants are selected from binders, carriers, lubricants, flow control agents, crystallization retarders, solubilizers, and coloring agents.
10. (original) The pharmaceutical composition of claim 1 in the form of a capsule or a tablet.
11. (original) The pharmaceutical composition of claim 1 or claim 10, comprising a dosage unit of 10 mg to 160 mg of telmisartan.
12. (original) The pharmaceutical composition of claim 10, comprising a dosage unit of 10 mg to 160 mg of telmisartan.
13. (original) A bilayer pharmaceutical tablet comprising:
- (a) a first telmisartan-containing tablet layer comprising the pharmaceutical composition of one of claims 1 to 9; and
  - (b) a second tablet layer containing a diuretic in a disintegrating tablet matrix.
14. (previously presented) A process for preparing the pharmaceutical composition of claim 1 using a fluid-bed granulation process, comprising:
- (i) preparing a granulation liquid as an aqueous solution by dissolving 3 wt.% to 50 wt.% of telmisartan together with the following components in water or in a mixture solution of ethanol and water:
    - (a) a basic agent in a molar ratio of basic agent:telmisartan of 1:1 to 10:1, and
    - (b) polyoxamers having an average molecular weight of about 2000 to 12000 in an amount of about 1 wt.% to about 20 wt.%;
  - (ii) placing 25 wt.% to 70 wt.% of a water-soluble diluent in a fluid-bed granulator, optionally together with 10 wt.% to 20 wt.% of a dry binder, including a premix-step;
  - (iii) carrying out the fluid-bed granulation using the granulation liquid for spraying on the components placed in the granulator;

- (iv) drying the granulation thus obtained and, optionally, screening the granulate obtained;
- (v) optionally blending the granulate with one or more additional excipients and/or adjuvants; and
- (vi) optionally milling the granulate thus obtained in order to produce a powdery composition of defined particle size distribution;

wherein all percentage amounts given are related to the final composition to be prepared.

15. (previously presented) A process for preparing the pharmaceutical composition of claim 1 using a spray drying process, comprising:

- (i) preparing an aqueous spray-solution by dissolving 3 wt.% to 50 wt.% of telmisartan together with the following components in water or mixture solution of ethanol and water:
  - (a) a basic agent in a molar ratio of basic agent:telmisartan of 1:1 to 10:1, and
  - (b) polyoxamers having an average molecular weight of about 2000 to 12000 in an amount of about 1 wt.% to 20 wt.%;
- (ii) spray-drying the aqueous spray-solution to obtain a spray-dried granulate;
- (iii) mixing the spray-dried granulate with 25 wt.% to 70 wt.% of a water-soluble diluent to obtain a premix;
- (iv) optionally mixing the premix with a lubricant;
- (v) optionally adding additional excipients and/or adjuvants in any of steps (i) to (iv),

wherein all percentage amounts given are related to the final composition to be prepared.